このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

喉頭癌の定位的 HYpofractionateD RadioAblative (HYDRA) 治療の試験

2026年10月5日 更新者:M.D. Anderson Cancer Center

喉頭癌の定位的 HYpofractionateD RadioAblative (HYDRA) 治療の第 I 相試験

To find the highest tolerable dose of stereotactic hypofractionated radioablation (HYDRA) radiation that can be given to patients with laryngeal cancer. The safety of this radiation will also be studied.

調査の概要

状態

募集

条件

介入・治療

詳細な説明

Study Groups:

If participant is found to be eligible to take part in this study, participant will be assigned to a radiation level of HYDRA radiation based on when participant joins this study. Up to 5 dose levels of HYDRA radiation will be tested. Up to 10 participants will be enrolled at each dose level. The first group of participants will receive the lowest dose level. Each new group will receive a higher dose than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of HYDRA radiation is found.

HYDRA Radiation Administration:

If participant is found to be eligible to take part in this study, participant will receive HYDRA radiation on up to 5 days over the course of about 2 weeks.

During radiation, participant will be asked to lie still for about 30-45 minutes. To help make sure that participant's head and neck do not move, participant will wear a head and neck mask. Participant will then have CT or PET-CT scans to make sure that participant is in the right position before participant begins HYDRA radiation. The actual HYDRA radiation treatment will take about 5-10 minutes to complete.

Length of Study Participation:

Participant may continue receiving HYDRA radiation for up to 2 weeks and for a total of 5 times. Participant will no longer be able to receive the study radiation if the disease gets worse, if intolerable side effects occur, or if participant is unable to follow study directions.

Participation on this study will be over after Long-Term Follow-Up. Long-Term Follow-Up may take up to 10 years.

Study Visits:

On Days that participant receives HYDRA:

  • Participant will have a speech pathology exam to check participant's voice, swallowing, and breathing function.
  • Participant will complete the same 5 questionnaires that participant did at screening.

Follow-Up Visits:

About 6 weeks after participant's last dose of HYDRA radiation:

  • Participant will have a physical exam.
  • Participant will have a videostroboscopy to check the status of the disease.
  • Participant will have a speech pathology exam.
  • Participant will have a CT or PET-CT scan to check the status of the disease.
  • Participant will complete the same 5 questionnaires that participant did at screening.
  • If the doctor thinks it is needed, participant will have a laryngoscopy to check the status of the disease. A laryngoscopy is a standard procedure in which a tube with a lighted camera is inserted through participant's mouth and into participant's throat.
  • If the doctor thinks it is needed, participant will have a core biopsy to check the status of the disease. To perform a core biopsy, a sample of tissue is removed using a hollow core needle that has a cutting edge.

About 3 months after participant's last dose of HYDRA radiation:

  • Participant will have a physical exam.
  • Participant will have a modified barium swallow to test participant's swallowing function and to check the status of the disease.
  • Participant will have a CT or PET-CT scan to check the status of the disease.
  • Participant will complete the same 5 questionnaires that participant did at screening.
  • If the doctor thinks it is needed, participant will have a laryngoscopy to check the status of the disease.
  • If the doctor thinks it is needed, participant will have a core biopsy to check the status of the disease.

About 6 months after participant's last dose of HYDRA radiation:

  • Participant will have a physical exam.
  • Participant will have a videostroboscopy to check the status of the disease.
  • Participant will complete the same 5 questionnaires that participant did at screening.
  • If the doctor thinks it is needed, participant will have a CT or PET-CT scan to check the status of the disease.
  • If the doctor thinks it is needed, participant will have a speech pathology exam.
  • If the doctor thinks it is needed, participant will have a laryngoscopy to check the status of the disease.
  • If the doctor thinks it is needed, participant will have a core biopsy to check the status of the disease.

Long-Term Follow-Up:

After participant's 6 month follow-up visit, every 3 months for the first 2 years, and then every 6 months after that for up to 5 years:

  • Participant will have a physical exam.
  • Participant will have a videostroboscopy to check the status of the disease.
  • Participant will have a speech pathology exam.
  • Participant will have a modified barium swallow to test participant's swallowing function and to check the status of the disease. This will only be done between 3-6 months and then 18-24 months after the first HYDRA dose.
  • Participant will complete the same 5 questionnaires that participant did at screening.
  • If the doctor thinks it is needed, participant will have a CT or PET-CT scan to check the status of the disease.
  • If the doctor thinks it is needed, participant will have a laryngoscopy to check the status of the disease.
  • If the doctor thinks it is needed, participant will have a core biopsy to check the status of the disease.

This is an investigational study. HYDRA radiation is delivered using methods that are not FDA-approved or commercially available. It is currently being used for research purposes only. The study doctor can explain how the radiation is designed to work.

Up to 50 participants will be enrolled in this study. All will take part at MD Anderson.

研究の種類

介入

入学 (推定)

11

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Texas
      • Houston、Texas、アメリカ、77030
        • 募集
        • MD Anderson Cancer Center
        • コンタクト:
        • 主任研究者:
          • Jack Phan, MD,PHD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Patients older than 18 years of age with histologically proven squamous cell carcinoma of the larynx.
  2. Stage T1N1/T2-4aN0-1 disease, as defined by American Joint Committee on Cancer (AJCC) criteria.
  3. ECOG (Zubrod) performance status 0-2.
  4. Must be functionally and technically fit for partial laryngectomy. Subsite study candidates will be evaluated by enrolling physician. The assessment checklist will be submitted at time of enrollment and evaluated by Dr. Gross or Dr. Phan.
  5. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  6. A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: *Has not undergone a hysterectomy or bilateral oophorectomy; or *Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
  7. Ability to understand English language and the willingness to sign a written informed consent.

Exclusion Criteria:

  1. Patients who have undergone resection of primary disease.
  2. Patients who have received induction chemotherapy for their cancer diagnosis.
  3. Patients who have undergone a diverting tracheostomy which is either a) traversing directly through tumor, b) has been placed for true airway insufficiency. Patients with a tracheostomy placed preemptively for impending airway compromise remain eligible for enrollment.
  4. Prior cancer diagnosis, except appropriately treated localized epithelial skin cancer or cervical cancer.
  5. Prior radiation therapy to the head and neck region.
  6. Women of childbearing potential (a woman of child-bearing potential is a reproductively mature woman who has not undergone a hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months [i.e., who has had menses at any time in the preceding 24 consecutive months]) and male participants must practice effective contraception (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) throughout the study.
  7. Patients unable or unwilling to give written, informed consent.
  8. Severe, active co-morbidity, defined as follows: a. Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months. b. Transmural myocardial infarction within the last 6 months. c. Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration. d. Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days before registration. e. Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and f. Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. Protocol-specific requirements may also exclude immuno-compromised patients.
  9. Exclusion #8 continued: g. History of treatment with potent immunosuppressive drugs for such conditions as post organ transplant, severe rheumatoid arthritis, etc. within the past 6 months.
  10. Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants
  11. Evidence of metastatic disease

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Stereotactic Hypofractionated Radioablation (HYDRA)

Participants receive HYDRA radiation on up to 5 days over the course of about 2 weeks, and for a total of 5 times.

Questionnaires completed at Baseline, on days receiving HYDRA, 6 weeks after last dose of HYDRA, 3 months after last dose of HYDRA, and 6 months after last dose of HYDRA. Also after the 6 month follow-up visit, every 3 months for the first 2 years, and then every 6 months after that for up to 5 years.

Starting dose is 8.0 Gy per fraction for 5 fractions (total dose = 40.0 Gy). Subsequent cohorts of participants receive an additional 0.5 Gy per fraction.

他の名前:
  • ヒドラ

Quality of life and symptom questionnaires completed at: Baseline, on days receiving HYDRA, 6 weeks after last dose of HYDRA, 3 months after last dose of HYDRA, and 6 months after last dose of HYDRA. Also after the 6 month follow-up visit, every 3 months for the first 2 years, and then every 6 months after that for up to 5 years.

他の名前:
  • 調査

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Maximum Tolerated Dose (MTD) of Stereotactic Hypofractionated RadioAblative (HYDRA) Treatment
時間枠:180 days

Toxicity graded using the NCI Common Toxicity Criteria for Adverse Events (CTCAE) v. 4.0.

180 days

二次結果の測定

結果測定
メジャーの説明
時間枠
Overall Complete Response Rate of Stereotactic Hypofractionated RadioAblative (HYDRA) Treatment
時間枠:10 years

Overall complete response rate with laryngeal HYDRA measured from duration of time from start of treatment to primary disease relapse.

10 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:Jack Phan, MD, PHD、M.D. Anderson Cancer Center

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2017年8月9日

一次修了 (推定)

2027年6月1日

研究の完了 (推定)

2027年6月1日

試験登録日

最初に提出

2017年4月11日

QC基準を満たした最初の提出物

2017年4月11日

最初の投稿 (実際)

2017年4月14日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月6日

QC基準を満たした最後の更新が送信されました

2026年10月5日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 2016-1023
  • NCI-2018-01164 (レジストリ識別子:NCI CTRP-Clinical Trials Registry)

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。